Mission.
Medikine, Inc. is a privately-held, seed-stage biotech with the mission of discovering agonists (i.e., activators) of clinically relevant cytokine receptors. Illustrating the clinical importance of cytokine receptor modulation, inhibition of cytokine receptor activity has led to some of the most valuable pharmaceutical products of the last three decades – e.g. Humira and Enbrel for rheumatoid arthritis, and Avastin and Herceptin for cancer. Development of activators of cytokine receptors has proven more difficult, and so many product opportunities with potentially significant clinical benefit remain unrealized. Medikine is utilizing a proprietary platform to identify a novel class of cytokine receptor agonists that are low molecular weight peptides, unrelated in sequence to the natural cytokine proteins, which can be engineered to have fewer side effects and greater efficacy than the natural cytokines.
Discovery Programs.
Medikine is prosecuting two discovery programs:
Leadership.
Medikine's experienced management team is composed of scientist-entrepreneurs who have successfully worked together in previous companies to obtain financing, build teams, invent and employ drug discovery technologies, and develop drugs through human trials and FDA-approval.
Contact Us.
info@medikine.com
1455 Adams Dr., Suite 1180
Menlo Park, CA 94025
USA